AHB-137: First-in-Human Study Shows Promising Antiviral Activity and Safety in Chronic Hepatitis B Management
Highlight
This first-in-human Phase 1 clinical trial evaluated AHB-137, a novel unconjugated antisense oligonucleotide (ASO) targeting a conserved region near the 3′ end of HBV mRNA, in healthy subjects and patients with chronic hepatitis B (CHB). The study demonstrated that AHB-137 is well tolerated with mostly mild adverse events, exhibits predictable pharmacokinetics including rapid absorption and a long half-life, and induces rapid and sustained reductions in hepatitis B surface antigen (HBsAg), a key marker of viral activity.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.